|
Synonyms: compound 352 [WO2023141432] | MXE-829 | MXE829 | MZE829
Compound class:
Synthetic organic
Comment: Alcedaplin (MXE829) is an apolipoprotein L1 (APOL1) inhibitor/modulator that is proposed to treat APOL1-associated nephropathy, particularly in individuals with a high-risk APOL1 genotype [1]. It is designed to inhibit both APOL1 pore formation and channel function.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 14123 | alcedaplin |
Synonyms ![]() |
| compound 352 [WO2023141432] | MXE-829 | MXE829 | MZE829 |
Database Links ![]() |
|
| GtoPdb PubChem SID | 530846930 |
| PubChem CID | 169031025 |
| Search Google for chemical match using the InChIKey | SFKXAXOEKZVXDA-CKQQTVSASA-N |
| Search Google for chemicals with the same backbone | SFKXAXOEKZVXDA |
| Search PubMed clinical trials | alcedaplin |
| Search PubMed titles | alcedaplin |
| Search PubMed titles/abstracts | alcedaplin |
| UniChem Compound Search for chemical match using the InChIKey | SFKXAXOEKZVXDA-CKQQTVSASA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | SFKXAXOEKZVXDA-CKQQTVSASA-N |